The patient was put on 7 + 3 induction regimen which included cytarabine (200 mg/[m.sup.2] x 2/7 days) and
idarubicin (12 mg/[m.sup.2]/day).
The induction phase is operationalized as seven days of intravenous (IV) cytarabine plus three days of either daunorubicin or
idarubicin, based on randomized controlled trial results from trials conducted in the 1980s (Rai et al.
The patient was administered 3+7 (
Idarubicin + Cytarabine) remission induction treatment and IDAC (
Idarubicin + Cytarabine) chemotherapy as consolidation treatment due to moderate-risk AML.
The trial's protocol provides for administration of the investigational drug in combination with MEC (mitoxantrone, etoposide and ara-C) or in combination with FAI (fludarabine, ara-C and
idarubicin), both of which are standard of care for this indication in the United States.
[27], who studied the permeation of cytostatics (bleomycin, dacarbazine, daunorubicin, etoposide, etoposide phosphate, ifosfamide,
idarubicin, irinotecan, mitomycin, mitoxantrone, oxaliplatin, teniposide, topotecan, and vinorelbine) through natural rubber latex and chloroprene rubber using HPLC with a ultraviolet-visible (UV-VIS) detector.
This vigorous multi-modality regimen showed improved survival rate over conventional therapy.3 Ferreri et al., based their phase II trial on MATILDE regimen which included high dose methotrexate combined with CNS penetrating chemotherapeutic agents (cytarabine,
idarubicin and thiotepa) followed by response tailored radiotherapy.
Kaposi's sarcoma; Idamycin (
idarubicin hydrochloride), approved in
He received the FLAI regimen including fludarabine, cytarabine, and
idarubicin (FLAI).
Patients were excluded if they had received treatment with curative intent after diagnosis of advanced disease; received treatment with doxorubicin, daunorubicin,
idarubicin, or other anthracyclines or anthracenediones (e.g., mitoxantrone) at any time before initiating first-line treatment for advanced STS; had evidence of concurrent malignancy, except adequately treated nonmelanoma skin cancer or in situ neoplasm; or had received first-line treatment within an interventional clinical trial (however, those who participated in post-first-line interventional trials or any noninterventional studies were eligible).
She was continued on an induction course of chemotherapy including ATRA, dexamethasone,
idarubicin, and arsenic trioxide.